Fundamental ScoreFundamental Score (0–100) sums 12 weighted components: Net Margin 10 · ROE 10 · Revenue Growth 12 · Op Margin 8 · Gross Margin 7 · Earnings Growth 8 · Current Ratio 10 · Quick Ratio 10 · D/E 10 · PEG 5 · P/B 5 · Piotroski F-Score 5.
Each metric maps to its points by smooth interpolation (no cliff at a threshold), and the margin/ROE anchors are sector-adjusted — a 10% net margin reads differently for a retailer than for a SaaS company. Missing inputs score a documented neutral rather than zero.
24/100
Poor
Stock
Net Margin0/10
ROE0/10
Operating Margin0/8
Gross Margin0/7
Current Ratio4/8
Quick Ratio3.5/7
Debt / Equity2.5/5
Interest Coverage2.5/5
Revenue Growth0/10
Key Metrics
Sector
Healthcare
↺
Sector
Broad industry category for peer benchmarking. Valuations and margins vary dramatically by sector — always compare within the same group, not across sectors.
↺
Industry
Medical Instruments & Supplies
↺
Industry
Specific peer group within the sector. P/E ratios only mean something relative to industry peers — not across unrelated industries.
↺
Quote Type
EQUITY
↺
Quote Type
Classifies the security as a stock, ETF, or fund. Determines the scoring model applied — ETFs are evaluated on fees and AUM, not profitability.
↺
Market Cap
$10.4B
↺
Market Cap
Total market value of all shares outstanding. Large caps offer stability; small caps carry more risk but can deliver outsized returns.
↺
P/E Ratio
n/a
↺
P/E Ratio
Dollars paid per dollar of annual earnings. High P/E implies growth expectations; low P/E can signal value or distress. Always compare within the same sector.
↺
P/B Ratio
4.41
↺
P/B Ratio
Market price vs. accounting book value. Below 1.0 may signal deep value or distress. High P/B is normal for asset-light, high-ROE businesses like software.
↺
Financial Statements
Data not available for this ticker.
Earnings Quality
Cash Conversion
n/a
↺
Cash Conversion Ratio
Operating cash flow ÷ net income. Above 1.0 means the company generates more cash than it reports in earnings — a sign of high-quality, conservative accounting. Below 0.5 is a red flag.
↺
Accruals Ratio
n/a
↺
Accruals Ratio
(Net income − Operating CF) ÷ Total assets. Measures how much earnings rely on accounting accruals vs. real cash. Negative is excellent; above 5% signals aggressive accounting.
↺
Quality Score
0/100
↺
Quality Score
Composite 0–100 based on cash conversion and accruals ratio. 75+ = High Quality, 50–74 = Moderate, 25–49 = Low Quality, <25 = Concerning.
↺
ConcerningHistorical trend
Year
Net Income
Operating CF
Cash Conv.
Accruals
iRepligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Earnings Growth0/7
FCF Yield4/8
EV / EBITDA2.5/5
PEG Ratio2/5
Piotroski F-Score2.5/5
Dividend Yield
n/a
↺
Dividend Yield
Annual dividends as a % of share price. Yields above 6–7% often signal the stock price has fallen sharply and the payout may be unsustainable.
↺
Beta
1.12
↺
Beta
Sensitivity to S&P 500 moves. A beta of 1.5 means the stock tends to move 1.5× the market in either direction — use to size positions relative to risk tolerance.
↺
52W High
$198.87
↺
52W High
Highest price over the past year. Stocks breaking above the 52-week high often keep going — no overhead resistance, and momentum buyers pile in.
↺
52W Low
$100.99
↺
52W Low
Lowest price over the past year. Proximity can signal distress or deep value — but a bounce off the low needs a catalyst to be actionable.
↺
Profit Margin
-1.5%
↺
Profit Margin
Net income as % of revenue. Above 20% signals pricing power. Shrinking margins signal rising costs or increasing competitive pressure on the business.
↺
ROE
-0.6%
↺
ROE
Return on Equity: net income ÷ shareholders' equity. Measures how efficiently management turns capital into profit. Above 15–20% is strong — Buffett's primary quality filter.
↺
Revenue Growth
10.9%
↺
Revenue Growth
Year-over-year change in total sales. No revenue growth limits earnings growth options. Sustained growth above 15% per year is exceptional in any sector.